Becton Dickinson and Company (BDX) - Total Assets

Latest as of December 2025: $54.84 Billion USD

Based on the latest financial reports, Becton Dickinson and Company (BDX) holds total assets worth $54.84 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BDX book value for net asset value and shareholders' equity analysis.

Becton Dickinson and Company - Total Assets Trend (1985–2025)

This chart illustrates how Becton Dickinson and Company's total assets have evolved over time, based on quarterly financial data.

Becton Dickinson and Company - Asset Composition Analysis

Current Asset Composition (September 2025)

Becton Dickinson and Company's total assets of $54.84 Billion consist of 16.7% current assets and 83.3% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $641.00 Million 1.5%
Accounts Receivable $2.99 Billion 5.4%
Inventory $3.89 Billion 7.0%
Property, Plant & Equipment $7.88 Billion 14.3%
Intangible Assets $2.99 Billion 5.4%
Goodwill $33.02 Billion 59.7%

Asset Composition Trend (1985–2025)

This chart illustrates how Becton Dickinson and Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Becton Dickinson and Company (BDX) market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Becton Dickinson and Company's current assets represent 16.7% of total assets in 2025, a decrease from 46.5% in 1985.
  • Cash Position: Cash and equivalents constituted 1.5% of total assets in 2025, down from 9.5% in 1985.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 64.0% of total assets, an increase from 1.0% in 1985.
  • Asset Diversification: The largest asset category is goodwill at 59.7% of total assets.

Becton Dickinson and Company Competitors by Total Assets

Key competitors of Becton Dickinson and Company based on total assets are shown below.

Company Country Total Assets
Caina Technology Co. Ltd.
SHE:301122
China CN¥1.93 Billion
Mark Dynamics Indonesia Tbk PT
JK:MARK
Indonesia Rp980.33 Billion
GETS Global Bhd
KLSE:5079
Malaysia RM400.10 Million
QITIAN Technology Group Co Ltd
SHE:300061
China CN¥1.41 Billion
Sartorius Aktiengesellschaft
XETRA:SRT3
Germany €9.61 Billion
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
USA $32.49 Million
Ansell Ltd
AU:ANN
Australia AU$3.32 Billion
Nanosonics Ltd
AU:NAN
Australia AU$272.48 Million

Becton Dickinson and Company - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.05 1.13 1.86
Quick Ratio 0.58 0.63 1.32
Cash Ratio 0.08 0.09 0.00
Working Capital $428.00 Million $995.00 Million $4.62 Billion

Becton Dickinson and Company - Advanced Valuation Insights

This section examines the relationship between Becton Dickinson and Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.80
Latest Market Cap to Assets Ratio 0.75
Asset Growth Rate (YoY) -3.4%
Total Assets $55.33 Billion
Market Capitalization $41.62 Billion USD

Valuation Analysis

Below Book Valuation: The market values Becton Dickinson and Company's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Becton Dickinson and Company's assets decreased by 3.4% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Becton Dickinson and Company (1985–2025)

The table below shows the annual total assets of Becton Dickinson and Company from 1985 to 2025.

Year Total Assets Change
2025-09-30 $55.33 Billion -3.42%
2024-09-30 $57.29 Billion +8.54%
2023-09-30 $52.78 Billion -0.29%
2022-09-30 $52.93 Billion -1.76%
2021-09-30 $53.88 Billion -0.24%
2020-09-30 $54.01 Billion +4.19%
2019-09-30 $51.84 Billion -3.83%
2018-09-30 $53.90 Billion +42.85%
2017-09-30 $37.73 Billion +47.48%
2016-09-30 $25.59 Billion -4.60%
2015-09-30 $26.82 Billion +115.47%
2014-09-30 $12.45 Billion +2.45%
2013-09-30 $12.15 Billion +6.94%
2012-09-30 $11.36 Billion +8.92%
2011-09-30 $10.43 Billion +8.08%
2010-09-30 $9.65 Billion +3.72%
2009-09-30 $9.30 Billion +17.59%
2008-09-30 $7.91 Billion +7.96%
2007-09-30 $7.33 Billion +7.40%
2006-09-30 $6.82 Billion +12.39%
2005-09-30 $6.07 Billion +5.55%
2004-09-30 $5.75 Billion +3.24%
2003-09-30 $5.57 Billion +10.55%
2002-09-30 $5.04 Billion +4.96%
2001-09-30 $4.80 Billion +6.60%
2000-09-30 $4.51 Billion +1.53%
1999-09-30 $4.44 Billion +15.37%
1998-09-30 $3.85 Billion +24.86%
1997-09-30 $3.08 Billion +6.59%
1996-09-30 $2.89 Billion -3.66%
1995-09-30 $3.00 Billion -5.06%
1994-09-30 $3.16 Billion +2.33%
1993-09-30 $3.09 Billion -2.84%
1992-09-30 $3.18 Billion +14.31%
1991-09-30 $2.78 Billion +7.19%
1990-09-30 $2.59 Billion +14.25%
1989-09-30 $2.27 Billion +9.80%
1988-09-30 $2.07 Billion +9.30%
1987-09-30 $1.89 Billion +11.86%
1986-09-30 $1.69 Billion +36.26%
1985-09-30 $1.24 Billion --

About Becton Dickinson and Company

NYSE:BDX USA Medical Instruments & Supplies
Market Cap
$41.62 Billion
Market Cap Rank
#639 Global
#300 in USA
Share Price
$146.31
Change (1 day)
-2.01%
52-Week Range
$145.31 - $210.02
All Time High
$278.09
About

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segme… Read more